CimetrA patent submitted to European IP office
Filed with ASX · · 2 pages · English
Earlier from Argent Biopharma
- Further findings on ArtemiC as anti-inflammatory agent
- $1M order for ArtemiC Rescue from swiss PharmaCan
- ArtemiC submitted to Health Canada
- March quarterly activity and cashflow report
- MGC pharma to acquire medical research company MediCaNL
Later from Argent Biopharma
- MGC pharma 2021 clinical trials program update
- CannEpil available for free dispensing in ireland
- 1St patient recruited into CimetrA phase 3 clinical trial
- Patent application lodged for novel drug delivery system
- MGC pharma executes US$24M US supply agreement
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma